Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma

Authors: Jian-Min Wu, Yan Xu, Nicholas J. Skill, Hongmiao Sheng, Zhenwen Zhao, Menggang Yu, Romil Saxena, Mary A. Maluccio

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Autotaxin (ATX) is an extracellular lysophospholipase D that generates lysophosphatidic acid (LPA) from lysophosphatidylcholine (LPC). Both ATX and LPA have been shown to be involved in many cancers. However, the functional role of ATX and the regulation of ATX expression in human hepatocellular carcinoma (HCC) remain elusive.

Results

In this study, ATX expression was evaluated in tissues from 38 human HCC and 10 normal control subjects. ATX was detected mainly in tumor cells within tissue sections and its over-expression in HCC was specifically correlated with inflammation and liver cirrhosis. In addition, ATX expression was examined in normal human hepatocytes and liver cancer cell lines. Hepatoma Hep3B and Huh7 cells displayed stronger ATX expression than hepatoblastoma HepG2 cells and normal hepatocytes did. Proinflammtory cytokine tumor necrosis factor alpha (TNF-α) promoted ATX expression and secretion selectively in Hep3B and Huh7 cells, which led to a corresponding increase in lysophospholipase-D activity. Moreover, we explored the mechanism governing the expression of ATX in hepatoma cells and established a critical role of nuclear factor-kappa B (NF-κB) in basal and TNF-α induced ATX expression. Further study showed that secreted enzymatically active ATX stimulated Hep3B cell invasion.

Conclusions

This report highlights for the first time the clinical and biological evidence for the involvement of ATX in human HCC. Our observation that links the TNF-α/NF-κB axis and the ATX-LPA signaling pathway suggests that ATX is likely playing an important role in inflammation related liver tumorigenesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Greten TF, Korangy F, Manns MP, Malek NP: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009, 100: 19-23. 10.1038/sj.bjc.6604784PubMedCentralCrossRefPubMed Greten TF, Korangy F, Manns MP, Malek NP: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009, 100: 19-23. 10.1038/sj.bjc.6604784PubMedCentralCrossRefPubMed
2.
go back to reference Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009, 27: 1485-1491. 10.1200/JCO.2008.20.7753PubMedCentralCrossRefPubMed Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009, 27: 1485-1491. 10.1200/JCO.2008.20.7753PubMedCentralCrossRefPubMed
3.
go back to reference Cooper AB, Wu JM, Lu D, Maluccio MA: Is Autotaxin (ENPP2) the Link between Hepatitis C and hepatocellular carcinoma?. J Gastrointest Surg. 2007, 11: 1628-1634. 10.1007/s11605-007-0322-9CrossRefPubMed Cooper AB, Wu JM, Lu D, Maluccio MA: Is Autotaxin (ENPP2) the Link between Hepatitis C and hepatocellular carcinoma?. J Gastrointest Surg. 2007, 11: 1628-1634. 10.1007/s11605-007-0322-9CrossRefPubMed
4.
go back to reference Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, Tejima K, Nishikawa T, Arai M, Yanase M: Plasma ysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 2007, 81: 1009-1015. 10.1016/j.lfs.2007.08.013CrossRefPubMed Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, Tejima K, Nishikawa T, Arai M, Yanase M: Plasma ysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 2007, 81: 1009-1015. 10.1016/j.lfs.2007.08.013CrossRefPubMed
5.
go back to reference Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992, 267: 2524-2529.PubMed Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992, 267: 2524-2529.PubMed
6.
go back to reference Lee HY, Clair T, Mulvaney PT, Woodhouse EC, Aznavoorian S, Liotta LA, Stracke ML: Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem. 1996, 271: 24408-24412. 10.1074/jbc.271.40.24408CrossRefPubMed Lee HY, Clair T, Mulvaney PT, Woodhouse EC, Aznavoorian S, Liotta LA, Stracke ML: Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem. 1996, 271: 24408-24412. 10.1074/jbc.271.40.24408CrossRefPubMed
7.
go back to reference Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene. 2000, 19: 241-247. 10.1038/sj.onc.1203263CrossRefPubMed Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene. 2000, 19: 241-247. 10.1038/sj.onc.1203263CrossRefPubMed
8.
go back to reference Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 2001, 61: 6938-6944.PubMed Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 2001, 61: 6938-6944.PubMed
9.
go back to reference Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006, 281: 25822-25830. 10.1074/jbc.M605142200CrossRefPubMed Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006, 281: 25822-25830. 10.1074/jbc.M605142200CrossRefPubMed
10.
go back to reference van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J: Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006, 26: 5015-5022. 10.1128/MCB.02419-05PubMedCentralCrossRefPubMed van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J: Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006, 26: 5015-5022. 10.1128/MCB.02419-05PubMedCentralCrossRefPubMed
11.
go back to reference Fox MA, Alexander JK, Afshari FS, Colello RJ, Fuss B: Phosphodiesterase-I alpha/autotaxin controls cytoskeletal organization and FAK phosphorylation during myelination. Mol Cell Neurosci. 2004, 27: 140-150. 10.1016/j.mcn.2004.06.002CrossRefPubMed Fox MA, Alexander JK, Afshari FS, Colello RJ, Fuss B: Phosphodiesterase-I alpha/autotaxin controls cytoskeletal organization and FAK phosphorylation during myelination. Mol Cell Neurosci. 2004, 27: 140-150. 10.1016/j.mcn.2004.06.002CrossRefPubMed
12.
go back to reference Dennis J, Nogaroli L, Fuss B: Phosphodiesterase-Ialpha/autotaxin (PD-Ialpha/ATX): A multifunctional protein involved in central nervous system development and disease. J Neurosci Res. 2005, 82: 737-742. 10.1002/jnr.20686CrossRefPubMed Dennis J, Nogaroli L, Fuss B: Phosphodiesterase-Ialpha/autotaxin (PD-Ialpha/ATX): A multifunctional protein involved in central nervous system development and disease. J Neurosci Res. 2005, 82: 737-742. 10.1002/jnr.20686CrossRefPubMed
13.
go back to reference Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002, 158: 227-233. 10.1083/jcb.200204026PubMedCentralCrossRefPubMed Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002, 158: 227-233. 10.1083/jcb.200204026PubMedCentralCrossRefPubMed
14.
go back to reference Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, Stracke ML: Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 2003, 63: 5446-5453.PubMed Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, Stracke ML: Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 2003, 63: 5446-5453.PubMed
15.
go back to reference Siess W: Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta. 2002, 1582: 204-215.CrossRefPubMed Siess W: Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta. 2002, 1582: 204-215.CrossRefPubMed
16.
go back to reference van Meeteren LA, Moolenaar WH: Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res. 2007, 46: 145-160. 10.1016/j.plipres.2007.02.001CrossRefPubMed van Meeteren LA, Moolenaar WH: Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res. 2007, 46: 145-160. 10.1016/j.plipres.2007.02.001CrossRefPubMed
17.
go back to reference Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H: Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004, 279: 17634-17639. 10.1074/jbc.M313927200CrossRefPubMed Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H: Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004, 279: 17634-17639. 10.1074/jbc.M313927200CrossRefPubMed
18.
go back to reference Kehlen A, Lauterbach R, Santos AN, Thiele K, Kabisch U, Weber E, Riemann D, Langner J: IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 2001, 123: 147-154. 10.1046/j.1365-2249.2001.01432.xPubMedCentralCrossRefPubMed Kehlen A, Lauterbach R, Santos AN, Thiele K, Kabisch U, Weber E, Riemann D, Langner J: IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 2001, 123: 147-154. 10.1046/j.1365-2249.2001.01432.xPubMedCentralCrossRefPubMed
19.
go back to reference Wullaert A, van Loo G, Heyninck K, Beyaert R: Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007, 28: 365-386. 10.1210/er.2006-0031CrossRefPubMed Wullaert A, van Loo G, Heyninck K, Beyaert R: Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007, 28: 365-386. 10.1210/er.2006-0031CrossRefPubMed
20.
go back to reference Morris AJ, Smyth SS: Measurement of autotaxin/lysophospholipase D activity. Methods Enzymol. 2007, 434: 89-104. full_textCrossRefPubMed Morris AJ, Smyth SS: Measurement of autotaxin/lysophospholipase D activity. Methods Enzymol. 2007, 434: 89-104. full_textCrossRefPubMed
21.
go back to reference Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN: Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog. 2009. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN: Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog. 2009.
22.
go back to reference Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431: 461-466. 10.1038/nature02924CrossRefPubMed Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431: 461-466. 10.1038/nature02924CrossRefPubMed
23.
go back to reference Kawagoe H, Soma O, Goji J, Nishimura N, Narita M, Inazawa J, Nakamura H, Sano K: Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2). Genomics. 1995, 30: 380-384. 10.1006/geno.1995.0036CrossRefPubMed Kawagoe H, Soma O, Goji J, Nishimura N, Narita M, Inazawa J, Nakamura H, Sano K: Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2). Genomics. 1995, 30: 380-384. 10.1006/geno.1995.0036CrossRefPubMed
24.
go back to reference Hooghe B, Hulpiau P, van Roy F, De Bleser P: ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res. 2008, 36: W128-132. 10.1093/nar/gkn195PubMedCentralCrossRefPubMed Hooghe B, Hulpiau P, van Roy F, De Bleser P: ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res. 2008, 36: W128-132. 10.1093/nar/gkn195PubMedCentralCrossRefPubMed
25.
go back to reference Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM: The antiinflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001, 8: 759-766. 10.1016/S1074-5521(01)00049-7CrossRefPubMed Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM: The antiinflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001, 8: 759-766. 10.1016/S1074-5521(01)00049-7CrossRefPubMed
26.
go back to reference Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA: NF-kB Inhibition in Human Hepatocellular Carcinoma and its Potential as Adjunct to Sorafenib Based Therapy. Cancer Letters. 2009, 278: 145-155. 10.1016/j.canlet.2008.12.031CrossRefPubMed Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA: NF-kB Inhibition in Human Hepatocellular Carcinoma and its Potential as Adjunct to Sorafenib Based Therapy. Cancer Letters. 2009, 278: 145-155. 10.1016/j.canlet.2008.12.031CrossRefPubMed
27.
28.
go back to reference Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009, 15: 539-550. 10.1016/j.ccr.2009.03.027PubMedCentralCrossRefPubMed Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009, 15: 539-550. 10.1016/j.ccr.2009.03.027PubMedCentralCrossRefPubMed
29.
go back to reference Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M: Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res. 1995, 76: 958-962.CrossRefPubMed Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M: Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res. 1995, 76: 958-962.CrossRefPubMed
30.
go back to reference Takahara N, Kashiwagi A, Maegawa H, Shigeta Y: Lysophosphati-dylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism. 1996, 45: 559- 10.1016/S0026-0495(96)90024-4CrossRefPubMed Takahara N, Kashiwagi A, Maegawa H, Shigeta Y: Lysophosphati-dylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism. 1996, 45: 559- 10.1016/S0026-0495(96)90024-4CrossRefPubMed
31.
go back to reference Zhu Y, Lin JH, Liao HL, Verna L, Stemerman MB: Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta. 1997, 1345: 93-98.CrossRefPubMed Zhu Y, Lin JH, Liao HL, Verna L, Stemerman MB: Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta. 1997, 1345: 93-98.CrossRefPubMed
32.
go back to reference Kume N, Gimbrone MA: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994, 93: 907-911. 10.1172/JCI117047PubMedCentralCrossRefPubMed Kume N, Gimbrone MA: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994, 93: 907-911. 10.1172/JCI117047PubMedCentralCrossRefPubMed
33.
go back to reference Chai YC, Howe PH, DiCorleto PE, Chisolm GM: Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells: evidence for release of FGF-2. J Biol Chem. 1996, 271: 17791-17777. 10.1074/jbc.271.30.17791CrossRefPubMed Chai YC, Howe PH, DiCorleto PE, Chisolm GM: Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells: evidence for release of FGF-2. J Biol Chem. 1996, 271: 17791-17777. 10.1074/jbc.271.30.17791CrossRefPubMed
34.
go back to reference Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci. 1998, 85: 2805-2809. 10.1073/pnas.85.8.2805.CrossRef Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci. 1998, 85: 2805-2809. 10.1073/pnas.85.8.2805.CrossRef
35.
go back to reference Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 1990, 344: 160-162. 10.1038/344160a0CrossRefPubMed Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 1990, 344: 160-162. 10.1038/344160a0CrossRefPubMed
36.
go back to reference Murugesan G, Fox PL: Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest. 1996, 97: 2736-2744. 10.1172/JCI118728PubMedCentralCrossRefPubMed Murugesan G, Fox PL: Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest. 1996, 97: 2736-2744. 10.1172/JCI118728PubMedCentralCrossRefPubMed
37.
go back to reference Coutant F, Perrin-Cocon L, Agaugué S, Delair T, André P, Lotteau V: Mature dendritic cell generation promoted by lysophosphatidylcholine. J Immunol. 2002, 169: 1688-1695.CrossRefPubMed Coutant F, Perrin-Cocon L, Agaugué S, Delair T, André P, Lotteau V: Mature dendritic cell generation promoted by lysophosphatidylcholine. J Immunol. 2002, 169: 1688-1695.CrossRefPubMed
38.
go back to reference Whalen MM, Doshi RN, Bader BW, Bankhurst AD: Lysophosphatidylcholine and arachidonic acid are required in the cytotoxic response of human natural killer cells to tumor target cells. Cell Physiol Biochem. 1999, 9: 297-309. 10.1159/000016324CrossRefPubMed Whalen MM, Doshi RN, Bader BW, Bankhurst AD: Lysophosphatidylcholine and arachidonic acid are required in the cytotoxic response of human natural killer cells to tumor target cells. Cell Physiol Biochem. 1999, 9: 297-309. 10.1159/000016324CrossRefPubMed
39.
go back to reference Sautin YY, Jorgensen M, Petersen BE, Saulnier-Blache JS, Crawford JM, Svetlov SI: Hepatic oval (stem) cell expression of endothelial differentiation gene receptors for lysophosphatidic acid in mouse chronic liver injury. J Hematother Stem Cell Res. 2002, 11: 643-649. 10.1089/15258160260194785CrossRefPubMed Sautin YY, Jorgensen M, Petersen BE, Saulnier-Blache JS, Crawford JM, Svetlov SI: Hepatic oval (stem) cell expression of endothelial differentiation gene receptors for lysophosphatidic acid in mouse chronic liver injury. J Hematother Stem Cell Res. 2002, 11: 643-649. 10.1089/15258160260194785CrossRefPubMed
40.
go back to reference Lowes KN, Brennan BA, Yeoh GC, Olynyk JK: Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol. 1999, 154: 537-541.PubMedCentralCrossRefPubMed Lowes KN, Brennan BA, Yeoh GC, Olynyk JK: Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol. 1999, 154: 537-541.PubMedCentralCrossRefPubMed
41.
go back to reference Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T: Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007, 41: 616-623. 10.1097/01.mcg.0000225642.90898.0eCrossRefPubMed Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T: Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007, 41: 616-623. 10.1097/01.mcg.0000225642.90898.0eCrossRefPubMed
42.
go back to reference Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006, 130: 1117-1128. 10.1053/j.gastro.2006.01.006CrossRefPubMed Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006, 130: 1117-1128. 10.1053/j.gastro.2006.01.006CrossRefPubMed
43.
go back to reference Coleman WB: Mechanisms of human hepatocarcinogenesis. Curr Mol Med. 2003, 3: 573-588. 10.2174/1566524033479546CrossRefPubMed Coleman WB: Mechanisms of human hepatocarcinogenesis. Curr Mol Med. 2003, 3: 573-588. 10.2174/1566524033479546CrossRefPubMed
44.
go back to reference Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB: Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979, 282: 615-616. 10.1038/282615a0CrossRefPubMed Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB: Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979, 282: 615-616. 10.1038/282615a0CrossRefPubMed
45.
go back to reference Blight KJ, McKeating JA, Rice CM: Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002, 76: 13001-13014. 10.1128/JVI.76.24.13001-13014.2002PubMedCentralCrossRefPubMed Blight KJ, McKeating JA, Rice CM: Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002, 76: 13001-13014. 10.1128/JVI.76.24.13001-13014.2002PubMedCentralCrossRefPubMed
46.
go back to reference Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982, 42: 3858-3863.PubMed Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982, 42: 3858-3863.PubMed
47.
go back to reference Everson GT, Polokoff MA: HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J Biol Chem. 1986, 261: 2197-2201.PubMed Everson GT, Polokoff MA: HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J Biol Chem. 1986, 261: 2197-2201.PubMed
48.
go back to reference Perilongo G, Shafford EA: Liver tumours. Eur J Cance. 1999, 35: 953-958. 10.1016/S0959-8049(99)00049-0.CrossRef Perilongo G, Shafford EA: Liver tumours. Eur J Cance. 1999, 35: 953-958. 10.1016/S0959-8049(99)00049-0.CrossRef
49.
go back to reference Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y: Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci. 2000, 905: 242-259.CrossRefPubMed Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y: Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci. 2000, 905: 242-259.CrossRefPubMed
50.
go back to reference Zhao Z, Xiao Y, Elson P, Tan H, Plummer SJ, Berk M, Aung PP, Lavery IC, Achkar JP, Li L: Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol. 2007, 25: 2696-2601. 10.1200/JCO.2006.08.5571CrossRefPubMed Zhao Z, Xiao Y, Elson P, Tan H, Plummer SJ, Berk M, Aung PP, Lavery IC, Achkar JP, Li L: Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol. 2007, 25: 2696-2601. 10.1200/JCO.2006.08.5571CrossRefPubMed
Metadata
Title
Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma
Authors
Jian-Min Wu
Yan Xu
Nicholas J. Skill
Hongmiao Sheng
Zhenwen Zhao
Menggang Yu
Romil Saxena
Mary A. Maluccio
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-71

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine